This content is machine translated Psoriasis in the Age of Precision Medicine Systemic Therapy for Patients with Comorbidities: What Is the Best Choice? Psoriasis is a chronic inflammatory systemic disease often associated with comorbidities, a fact that must be taken into account during treatment. Particular attention should be paid to psoriatic arthritis (PsA),...…
View Post 13 min This content is machine translated Obesity Treatment Oral GLP-1 Therapies: ATTAIN-1 and OASIS-4—The Next Leap Forward Injectable GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide have redefined pharmacological obesity treatment and achieved weight loss in the range of 15 to 20% in clinical trials. Nevertheless,...…
View Post 5 min This content is machine translated Mental Health with GLP-1 RAs Benefits of Semaglutide and Liraglutide GLP-1 receptor agonists are established treatments for type 2 diabetes and obesity. Depression and anxiety disorders are common among people with diabetes and obesity, and both conditions are associated with...…
View Post 12 min This content is machine translated The Brain and the Motivation to Eat Why is it so hard to lose weight? Obesity is the most common chronic disease in Western societies, with serious metabolic, cardiovascular, and psychosocial consequences. The therapeutic landscape has changed fundamentally: new-generation GLP-1 agonists achieve weight loss that,...… CME-Test
View Post 12 min This content is machine translated Global Recommendation, Swissmedic Approval, and SL Limitation WHO Guidelines on GLP-1 for Obesity With the guideline published on December 1, 2025, the World Health Organization has, for the first time, issued a globally applicable recommendation on the pharmacological management of obesity in adults....…
View Post 7 min This content is machine translated Obesity in Children and Adolescents Gene-Environment Interactions: Polygenic or Monogenic Determinants? In the context of precision medicine, a differentiated approach to the diagnosis of obesity provides an essential foundation for implementing improved strategies for prevention, treatment, and prognosis. Obesity is often...…
View Post 18 min This content is machine translated From Risk Identification to Anti-Inflammatory Intervention Inflammation as a Treatment Goal in Its Own Right For decades, cardiovascular prevention was essentially a story about cholesterol. Yet a significant proportion of patients experience adverse events despite optimally controlled lipid levels—a reflection of a residual risk that...… CME-Test
View Post 7 min This content is machine translated Geriatric patients Micronutrient Intake in Older Adults Extrinsic and intrinsic factors contribute to older adults being less likely to meet the recommended daily intake of micronutrients. This can have significant negative health consequences. Micronutrients that are particularly...…
View Post 12 min This content is machine translated Cardiology and Nutrition Ultra-Processed Foods and Cardiovascular Risk—The New AHA Position Ultra-processed foods (UPFs ) account for a significant portion of energy intake in Western countries—in the United States, an estimated more than half. Given this ubiquity and a growing number...…
View Post 7 min This content is machine translated Obesity: A Multimodal and Interdisciplinary Approach New Swiss Clinical Practice Guideline Provides Guidance The guidelines developed by Swiss professional associations (Swiss Obesity Clinical Practice Guidance) contain evidence-based recommendations for the diagnosis and treatment of obesity, with a focus on improving health, quality of...…
View Post 11 min This content is machine translated Cardiometabolism Retatrutid and the TRIUMPH Program: The Triple Agonist on the Horizon Incretin-based obesity therapy has advanced rapidly in just a few years: from GLP-1 receptor agonists (semaglutide) to the dual GIP/GLP-1 agonist tirzepatide and on to a triple agonist. Retatrutide (LY3437943)...…
